Partnering with Science: New Hope for the Effective Treatment of Type 2 Diabetes

  • Michael Blaber, PhD Florida State University College of Medicine

Abstract

Research scientists are exploring new physiological pathways and new therapeutics to regulate glucose in people living with type 2 diabetes. Studies have shown that fibroblast growth factor 21 (FGF-21) has the ability to regulate blood glucose levels; however, these effects are temporary. In another promising development, activation of the fibroblast growth factor receptor-1 (FGFR-1) using a specifically designed antibody has shown to be effective in regulating glucose and is capable of long residence times in the blood. Scientists are also exploring the role of FGF-1, another member of the FGF family, in fat remodeling and glucose regulation. It is possible that the regulation of blood glucose levels by FGF-1 might actually involve regulation of a neural pathway (as opposed to a systemic metabolic pathway). People living with diabetes can have hope that scientists are close to developing novel therapeutics to regulate glucose over an extended period of time.

Author Biography

Michael Blaber, PhD, Florida State University College of Medicine

Michael Blaber, PhD, is currently Professor of Biomedical Sciences at Florida State University College of Medicine. His research focus includes protein structure, stability and folding; mutational study of human fibroblast growth factor 1 for angiogenic therapy; structural biology and enzymology of human kallikrein-related peptidases; role of human kallikrein-related peptidase 6 in human disease.

Published
2017-02-09
Section
Review Articles